ArticleCirculation research2025
Excess Neprilysin in Placental EVs Impairs CNP-NPRB-Mediated Vasodilation to Trigger Preeclamptic Hypertension.
Article in Circulation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Cell-Surface Signatures and Targets of Modulated Vascular Smooth Muscle Cells in Atherosclerosis: From State Identification to Precision Intervention.Journal of cardiovascular development and disease · 2026Review
- Placental Small Extracellular Vesicles Undetected in Cerebrospinal Fluid of Preeclamptic and Eclamptic Women.Biomolecules · 2026Article
- The recent advancements of single-cell RNA sequencing in pre-eclampsia.Frontiers in medicine · 2026Review
- Neprilysin in Placental EVs as Culprits and Therapeutic Target for Preeclampsia.Circulation research · 2025Article
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreeclampsia is a placenta-origin pregnancy complication. Although its development has long been divided into 2 stages: abnormal placentation (stage I) and the release of factors from the hypoperfused placenta into circulation, triggering preeclampsia due to endothelial dysfunction (stage II), the placenta-derived substances coupling the 2 stages remain unclear.
methodsExtracellular vesicles (EVs) from normal and preeclampsia-complicated placentas were intravenously administered to pregnant mice, and blood pressure was recorded throughout pregnancy. The differential cargo, including NEP (neprilysin), of placental EVs in normal and preeclamptic placentas was identified by liquid chromatography-mass spectrometry, and the cell types involved in NEP expression in the placenta were determined by single-cell RNA sequencing. The effects of placental EVs and recombinant mouse NEP on the uterine arteries were assessed by myography. Placenta-specific NEP overexpression mice were established by in situ injection of adenovirus. The binding affinity between NEP and the vasodilative peptides was determined using an Octet instrument. NEP-overexpressing human umbilical vein endothelial cells were established to measure CNP (C-type natriuretic peptide) release and cocultured with NPRB (natriuretic peptide receptor-B) knockdown vascular smooth muscle cells (VSMCs) to measure cGMP production in VSMCs.
resultsPlacental EVs from preeclamptic pregnancies impaired vascular endothelium-dependent vasodilation and induced preeclampsia in mice. NEP was expressed predominantly by syncytiotrophoblasts and upregulated in placental EVs from preeclamptic pregnancies. Recombinant mouse NEP administration resulted in outcomes like those of administration of placental EVs from preeclamptic pregnancies. Placenta-specific NEP overexpression disturbed maternal hemodynamics, resulting in hypertension and proteinuria of the mice. CNP exhibited high binding affinity for NEP, and NEP upregulation in human umbilical vein endothelial cells inhibited CNP release, which further influenced the production of cGMP in VSMCs; however, this effect was largely blunted in NPRB-deficient VSMCs.
conclusionsExcessive NEP in placental EVs from preeclamptic pregnancies is transported into the endothelial cells of uterine and placental arteries to cleave and degrade CNP, resulting in compromised CNP paracrine activity and NPRB-mediated cGMP production in adjacent VSMCs and triggering the hypertensive manifestation of preeclampsia.
Indexed as
Identifiers
40304042What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.